ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
Here, we summarize a study by Afrough et al. published in Blood Cancer Journal on the impact of different bridging therapies on outcomes in patients…
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant ER-positive, HER2-negative breast cancer.
Webinar series by VJHemOnc featuring presentations & discussions on key abstracts in hematological malignancies presented at the ASCO & EHA 2024 meetings.
Webinar series by VJOncology from 19–24 June 2024 featuring presentations & discussions on selected abstracts from ASCO 2024
Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations.
Alan Percy, MD, Pediatric Neurologist at University of Alabama at Birmingham, describes the history of Rett syndrome.
Tenosynovial giant cell tumor (TGCT) is a rare benign tumor involving the joint synovium, bursae, and tendon sheath.
Michael Hayden, PhD, CEO of Prilenia, discusses recent clinical trials testing pridopidine for the treatment of ALS and Huntington’s disease.
Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs).
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest…